Study details
Enrolling now
Empagliflozin Treatment in Kidney Transplant Recipients
VA Office of Research and Development
NCT IDNCT06013865ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
264
Study length
about 6 years
Ages
19+
Locations
5 sites in IA, IL, NE +2
About this study
Researchers are testing whether empagliflozin, a medication, can improve outcomes for kidney transplant recipients. The trial will last 2186 days and involve approximately 264 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Empagliflozin
PhasePhase 4
DrugEmpagliflozin
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Blood Pressure, Body Weight, Death, Glycemic Control
Body systems
Renal